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Background: Data on the immunogenicity and safety of
acellular pertussis-based combination vaccines when given
in the WHO recommended EPI schedule (6, 10 and 14 weeks
of age) are needed for making individual clinical practice
and public policy decisions in India.
Methods: This study assessed the immunogenicity and
safety of primary vaccination at 6, 10 and 14 weeks of
age with PentaximTM (sanoﬁ pasteur, AcXim family vaccine)
including diphtheria, tetanus, acellular pertussis, inacti-
vated poliovirus, Haemophilus inﬂuenzae type b conjugate
(PRP-T)antigens in 226 infants in India. Antibody titers were
measured immediately before, and one month after, pri-
mary vaccination. Immunogenicity data from French infants
vaccinated at 2, 3 and 4 months was used as a reference.
Reactogenicity and safety were evaluated from parental
reports.
Results: One month after the third dose, 90.0% of sub-
jects had anti-PRP≥ 1.0g/mL, and the GMT increased
from 0.11g/mL to 4.17g/mL. Anti-Polio GMTs (1/dil U)
increased from 18.1 to 441, from 20.4 to 459, and from 9.9
to 1511 for types 1, 2 and 3, respectively. Two-fold increase
in PT and FHA antibody concentration occurred in 97.1%
and 92.4% of subjects, and anti-PT and anti-FHA antibody
titers≥ 25 EU/mL were observed in 100% and 97.6% of chil-
dren, respectively. The vaccine was well-tolerated, with low
reactogenicity. Severe solicited reactions were documented
in < 0.5% of subjects after any dose. No drop outs occurred
because of adverse events.
Conclusion: Pentaxim given at 6, 10 and 14 weeks of age
was well tolerated and induced large immune responses in
Indian infants, similar to those observed in French infants
vaccinated at 2, 3, 4 months of age in an earlier trial.
[NCT00259337].
doi:10.1016/j.ijid.2008.05.433
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Background: A human papillomavirus (HPV) 16/18 AS04
adjuvanted vaccine (CervarixTM, GlaxoSmithKline) has been
shown to be well-tolerated and immunogenic in females
aged 10—55 years, and effective for the prevention of HPV-
16/18 infections and associated precancerous lesions in
15—25 year-old women. Our study evaluated the immuno-
genicity and safety of CervarixTM in 10—18 year-old healthy
males.
Methods: This was a phase I/II, observer-blind, parallel-
group study (580299/011/NCT00309166). Males were ran-
domized (2:1 ratio) to receive CervarixTM (n = 181) or
hepatitis B vaccine (Engerix-BTM, GlaxoSmithKline) (n = 89)
at 0, 1 and 6 months and were followed for 7 months after
the ﬁrst dose.
Results: At Month 2, 100% of seronegative males in the
HPV group had seroconverted for HPV-16 and 18 (ELISA) and
remained seropositive at Month 7. At this time point, GMTs
were respectively 4-fold and 2-fold higher, as compared to
Month 2. The immune response to CervarixTM in 10-18 year-
old males was non-inferior for both seroconversion rates and
GMTs to that seen in 15—25 year-old females in a previous
study. The reactogenicity proﬁle of the vaccine in males was
similar to that reported in females. Compliance with 3-dose
course was equally high (97%) in both groups.
Conclusion: CervarixTM is immunogenic and well-
tolerated in 10—18 year-old males, inducing anti-HPV-16
and 18 antibody responses non-inferior to those previously
reported in 15—25 year-old females, among whom efﬁcacy
has been previously demonstrated. However, whether vac-
cination of adolescent males will ultimately prevent sexual
transmission of oncogenic HPV types or have public health
value remains to be determined.
doi:10.1016/j.ijid.2008.05.434
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Modulation of Interleukin-18 Produces a Positive Impact
on the Release of Proinﬂammatory and Antiinﬂammatory
Cytokines During Malaria Infection
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Malaria infection is associated with the release of proin-
ﬂammatory cytokines including TNF-alpha, IFN-gamma,
IL-1, and IL-6. These cytokines play important roles in medi-
ating the disease severity and involved in the pathogenesis
and immunopathological reactions during the infection.
IL-18 is a potent pro-inﬂammatory cytokine and inducer
of other cytokines release. In this study, we investigated the
effect of modulating IL-18 production on the release of pro-
inﬂammatory and anti-inﬂammatory cytokines (TNF-alpha,
IFN-gamma, IL-1, IL-6 and IL-10) during malaria infection.
Plasmodium berghei infection in ICR mice was used as
model for malaria infection. Mice were inoculated with par-
asitized red blood cells from donor mouse infected with
P. berghei. Control animals received normal uninfected
red blood cells. IL-18 production during the infection was
modulated by treatment with the rIL-18, rIL-18 binding
protein and anti-IL-18 monoclonal antibody. Blood samples
for plasma were collected from the animals on day 1, 3
and 5 following inoculation and treatment. ELISA method
